One challenge will be to determine if this effect is recapitulated in other cancers with recurrent MYCN amplification such as medulloblastoma and neuroendocrine prostate cancer or in the numerous cancers in which MYC is altered. This evidence concerns the gene MYCN and medulloblastoma.